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Objective: To describe the association of the rare and serious complication of liver toxicity in previously healthy
Grave’s disease (GD) patients after the treatment with radioactive iodine 131I (RAI).
Case presentation: We report the clinical, laboratory and pathologic findings of 2 cases of severe liver toxicity
associated with the treatment with RAI in previously healthy patients with GD. Clinical examination and laboratory
investigations excluded viral hepatitis, autoimmune hepatitis, granulomatous disease, primary biliary disease,
extrahepatic biliary obstruction, and heart failure.
Case 1: A previously healthy 52-years old man reportedly having a typical GD but following RAI treatment,
concomitantly developed severe liver toxicity that required 1 week of treatment in hospital.
Case 2: A previously healthy 34-years old woman is reported as having a typical GD but developed jaundice
following RAI treatment that required several weeks of in hospital treatment in the hepato-biliary department.
In both cases, the liver dysfunction resolved after intensive treatment with hepato-protective agents. In this report
the therapeutic considerations as well as the pathogenetic possibilities are reviewed.
Conclusion: To the best of our knowledge, this is the first description of the association observed, which is rare but
may be severe and should be considered in any case of thyrotoxicosis where a liver dysfunction develops after the
treatment with radioactive iodine 131I.
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Graves’ disease is the most common cause of hyperthy-
roidism in iodine-sufficient areas [1]. Several therapeutic
options are available for the treatment of hyperthyroid-
ism due to GD, including antithyroid drug medication
(ATD), near-total resection (NTR) and radioiodine ther-
apy (RIT). Each therapeutic option has its advantages
and disadvantages [2].
Oral administration of 131I has been used to treat be-
nign conditions of the thyroid gland since the 1940s [3].
In our hospital, the treatment with RAI was initiated in
1983. The aim of treatment with 131I is to achieve a
non-hyperthyroid status, which can be euthyroid or
hypothyroid, recompensated by levothyroxine medica-
tion [3]. RAI treatment is widely used because it is easy
to be administered, widely available, and effective in* Correspondence: qushencn@hotmail.com
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distribution, and reproduction in any mediummost patients [4]. To date, our nuclear medicine depart-
ment welcomes an average of 350 patients yearly for
RIT.
The usual treatment in our hospital is with a fixed ac-
tivity regimen that ranges between 5-7 mCi with a mean
effective half life (EHL) of 7.2 days.
Liver enzyme elevations in thyroid disease might be
paradoxically related to RIT. However, here we present
two cases of liver toxicity developing in previously healthy
Grave’s disease patients when treated with RAI, and
subsequent improvement via hepato-protective treatment
regimens. Our aim is to draw the attention of physicians
to hyperthyroidism and its treatment with RAI in the dif-
ferential diagnosis of liver dysfunction.
Case presentation
Case 1
A 52-year-old male patient was diagnosed with GD 20-
years ago with history of heat intolerance, sweating,
weight loss, tremors, increased appetite, accompanied bytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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was put on a treatment with anti-thyroid drug (ATD)
propylthiouracil, methimazole and prednisolone which
brought an improvement of the symptoms, exoph-
thalmos, and thyroid function. However, some 5-years
ago, he noticed an enlargement of the thyroid and 6-
months later, he complained of persistent profuse sweat-
ing, heat intolerance, palpitation, associated with neck
pain, mild breathing difficulty, there were no significant
weight loss and no significant increase in bowel move-
ments. He was put on methimazole (10 mg bid), which
proved ineffective. He denied having any history of
smoking, alcohol or drug abuse. There was no significant
past medical or surgical history.
He was admitted in our department in July 2012 and
upon physical examination, his blood pressure was 120/
82 mmHg, and heart rate of 98/min regular. He had
moist skin, tremors, bilateral moderate exophthalmos of
mean and no pedal oedema. His thyroid showed a bilat-
eral 3rd degree enlargement, soft in consistency, non
tender, no palpable nodules and no bruits upon auscul-
tation. Thyroid ultrasonography showed bilateral en-
largement of the thyroid gland and radioactive iodine
uptake test showed a significantly elevated thyroid 123I
uptake function at 2 and 24 hours of 95.7% and 71.4%
respectively. Orbital CT showed bilateral exophthalmos;
the prominence was of 19.0 mm and 19.3 mm Hertel
readings on the right and left sides respectively, abdom-
inal ultrasound showed no abnormalities. Blood chem-
ical tests documented normal renal function and hepatic
values but revealed a significant increase in serum thy-
roid hormone levels (Table 1). The possibility of primary
liver disease could be ruled out; there was no evidence
of immunological conditions (autoimmune hepatitis,
primary sclerosing cholangitis or primary biliary cirrho-
sis); neither was metabolic liver disease due to alpha-1
antitrypsin deficiency, hemochromatosis or Wilson´sTable 1 Chronological thyroid function test and liver function
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1ST admission 2012-07-11 30.0 84.0 0.02
2012-07-25 1st
7-days post-RAI dose 1 2012-07-31
After 1-week of liver protection
treatment 2012-08-06
2012-09-02 2nd
2nd Admission 2012-09-14 30.0 128.0 0.01
After 12-days of liver protection
treatment 2012-09-25 Discharge
30.0 112.0 0.24disease identified. Hepatitis serology was negative and ser-
ology for several other virus infections that might lead to
liver dysfunction did not indicate presence of active virus
infection. The patient´s alcohol consumption was sparse
limited to less than one drink a month. Grave’s hyperthy-
roidism was diagnosed and the treatment dosage for the
patient was determined by the intake rate and the size of
thyroid gland. If the dosages is over 10 mCi 131I, the pa-
tients will be treated in two divided doses of 5–7 mCi each
to minimise side-effects.
7-days after the first RAI dose of 5 mCi, the patient’s
blood chemical tests revealed an abnormal liver function
(Table 1), the abdominal ultrasound showed no abnor-
malities. The patient was treated with Essentiale Forte
NW [5] (Polyene Phosphatidyl Choline) and BicyclolW [6]
for liver protection and prednisolone (30 mg qd).
One week later, the blood investigations showed marked
recovery from the liver failure (Table 1).
About 5-weeks following the first RAI dose, the pa-
tient was subjected to his second dose of 5 mCi. 2-weeks
following the second RAI dose, the patient presented to
our department complaining of discomfort in the right
upper quadrant, loss of appetite, palpitation and light
coloured stools.
Upon admission, the blood tests revealed marked liver
dysfunction (Table 1). Abdominal ultrasound showed no
abnormalities. The patient was diagnosed with hepato-
toxicity following the administration of a dose of RAI.
The treatment regimen was aimed at liver protection
with injections of SamyrW [7] (ademetionine-1, 4-
butanedisulphonate) and Tianqing GanmeiW [8] (mag-
nesium isoglycyrrhizinate); intravenous Vitamin C [9]
administration, prednisolone (30 mg qd) and LeucogenW
[10] (asparaginase) to raise the white cell count.
The liver toxicity was resolved within 10-days (Table 1).
Upon discharge, the thyroid function test showed
(Table 1). In an outpatient review, 2 months later, thetest for case 1
1
Tb AST ALT AKP δGT ALB
.4-17.1
mol/L
<40 U/L <58 U/L 40–130 U/L <60 U/L 34–48 g/L
15.1 26.1 32.8 121.5 44.6 42.0
Dose of RAI
28.0 68.0 186.0 96.0 127.0 30.0
19.4 25.9 54.0 95.4 107.5 32.0
Dose of RAI
44.1 29.0 27.9 148.6 152.6 30.0
88.5 26.9 58.1 137.1 90.8 32.0
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liver function remained on the normal side.Case 2
A 34-years-old female patient was diagnosed 10-years
ago with GD with history of tremors, heat intolerance,
sweating, weight loss, increased appetite, irritability, in-
creased stool frequency and reduced menstrual flow and
was put on methimazole (5 mg qd). The patient self-
discontinued the treatment and upon review, the thyroid
hormones showed normalisation.
1-year after the discontinuation of medication, there was
a relapse and the patient was admitted to her treating-
hospital at the time. Upon discharge, the patient was put
back on methimazole (2.5 mg qd). 10-months ago, the pa-
tient attended our out-patient department for review. The
thyroid hormone levels showed a normalisation and the
treating physician advised to stop all medications.
12-days following the discontinuation of treatment,
the patient observed a recurrence of palpitation and
tremors. The patient was referred to our department for
a thyroid function test and the blood chemical tests doc-
umented normal renal function and hepatic values but
revealed a significant increase in serum thyroid hormone
levels (Table 2). A relapse of Grave’s hyperthyroidism
was diagnosed and 2 days later, she was admitted as in-
patient for treatment with RAI. The patient had good
mental health, good sleeping pattern, good appetite,
normal bowel frequency, normal urine and no significant
recent weight change. She had no history of taking
iodine-containing drug and no history of throat or neck
pain. The possibility of primary liver disease could be
ruled out; there was no evidence of immunological
conditions (autoimmune hepatitis, primary sclerosing
cholangitis or primary biliary cirrhosis); neither was
metabolic liver disease due to alpha-1 antitrypsin defi-
ciency, hemochromatosis or Wilson´s disease identified.
Hepatitis serology was negative and serology for several
other virus infections that might lead to liver dysfunc-
tion did not indicate presence of active virus infection.Table 2 Chronological thyroid function test and liver function
Case








1st admission 2011-12-05 16.67 53.15 0.02
2011-12-08 D
2nd admission 2011-12-15 11.42 40.21 0.01
After 13-days of liver protection
treatment 2011-12-28 Transfer
to hepato-biliary department
9.38 44.1 0.09The patient´s alcohol consumption was sparse limited
to less than one drink a month.
Upon examination, she had 2nd degree bilateral thy-
roid enlargement, soft in consistency, non tender, no
palpable nodules and no thyroid bruit on auscultation.
Chest X-ray was normal, abdominal ultrasound showed no
abnormalities, orbital CT showed bilateral exophthalmos;
the prominence was of 19.1 mm and 18.8 mm Hertel read-
ings on right and left sides respectively. Thyroid scan
showed bilateral lobe swelling and radioactive Iodine up-
take test showed a significantly elevated thyroid 123I uptake
function at 2 and 24 hours of 40% and 59.0% respectively.
She received RIT (10 mCi) and was discharged the follow-
ing day on 30 mg of prednisolone per day.
5-days following the RAI treatment, the patient
started complaining of a mild sense of nausea; she
underwent serological investigations, which pointed
towards a hepatic dysfunction (Table 2). The patient
was readmitted, her liver function test showed hep-
atotoxicity (Table 2), abdominal ultrasound did not
show any abnormal finding and the following treat-
ment was administered: AtomolanW [11] (reduced
glutathione tablets), Essentiale Forte NW [5] (polyene
phosphatidyl choline injection) and BifendateW [12] as
liver protective treatment, prednisolone (30 mg qd)
and LeucogenW [6] (asparaginase) to raise white blood
cells.
13-days after the second admission, despite the inten-
sive hepato-protective treatment, the patient’s liver func-
tion markers remained elevated with the exception of
the alanine aminotransferase (ALT) (Table 2). The pa-
tient was eventually transferred to the Hepato-biliary de-
partment to continue her intensive treatment. 3-weeks
later, her liver function tests were back to normal and
she was ultimately discharged from the Hepato-biliary
department. Till date, the liver function is normal and
she is currently euthyroid.
Discussion
The present patients had concomitant thyrotoxicosis and
hepatic dysfunction from treatment with RAI. Both patientstest for case 2
2
Tb AST ALT AKP δGT ALB
.4-17.1
Umol/L
<40 U/L <58 U/L 40–130
U/L
<60 U/L 34–48 g/L
4.8 37.0 52.0 58.0 26.0 75.0
ose of RAI
28.4 407.0 796.0 168.0 188.0 40.0
130.8 59.0 29.0 111.0 54.0 38.0
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concerning the cause of liver disease. In these cases,
isolated liver dysfunction could be seen, which was in ac-
cordance with the liver enzymes that showed predominant
signs of liver dysfunction. The possibility of primary liver
disease could be ruled out as mentioned in the described
cases above.
Liver injury caused by thyrotoxicosis is relatively com-
mon and can be conveniently divided into hepatitic or
cholestatic types [13].
Iodine is an indispensable component of thyroid hor-
mones levothyroxine (T4) and triiodothyronine (T3). Thy-
roid cells extract and concentrate iodide from plasma [14].
The liver is the primary organ of thyroid hormone me-
tabolism. This partly explains the complexity of the
influences of increased thyroid hormone levels on liver
function tests. Individual differences are attributed to
liver enzyme levels [15].
Hepatic radioiodine uptake was positively correlated
with the dose of administered I-131 and increased
levels of serum AST and ALT [16]. In our patients,
several factors are able to potentiate the RAI-induced
hepatotoxicity, i.e. age (adults are generally more sus-
ceptible to hepatotoxicity than children), sex (women
are more commonly affected than men), nutritional
factors (malnutrition). Moreover, we also noted a
probable relationship of the period of disease (long
standing Grave’s disease), dose-related (high dose of RAI),
size of the goitre (both patients had very enlarged thyroid
lobes) with the increased susceptibility to develop
hepatotoxicity.
When hyperthyroidism due to GD persists after 6
months following 131I therapy, or if there is minimal re-
sponse 3 months after therapy, retreatment with 131I is
suggested [17].Conclusion
Although hepatic toxicity is a rather uncommon event
after RAI treatment, physicians should be aware of this
probable complication and consider starting an early
hepato-protective treatment regimen prior to adminis-
tration of RAI.
While there are controversies in treatment of thyro-
toxicosis with RAI, with appropriate patient selection
and regular follow-up, radioiodine is a safe and effective
modality in achieving high cure rates [18].Consent
Written informed consent was obtained from the patients
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
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